|1.||Puri, Raj K: 5 articles (07/2005 - 07/2002)|
|2.||Pan, Henry: 2 articles (07/2005 - 08/2003)|
|3.||Husain, Syed R: 2 articles (10/2003 - 07/2002)|
|4.||Kawakami, Mariko: 2 articles (10/2003 - 07/2002)|
|5.||Kawakami, Koji: 2 articles (10/2003 - 07/2002)|
|6.||Puri, R K: 2 articles (01/2003 - 06/2000)|
|7.||Rand, R W: 2 articles (01/2003 - 06/2000)|
|8.||Gitlitz, Barbara: 1 article (07/2005)|
|9.||de Haan, Hans: 1 article (07/2005)|
|10.||Figlin, Robert: 1 article (07/2005)|
07/01/2005 - "Low circulating levels of NBI-3001, coupled with rising NAB titers, may have contributed to the lack of response in tumors that express IL-4R."
10/15/2003 - "Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1."
07/01/2002 - "Sixty percent of animals treated with intratumoral injections of IL4-Pseudomonas exotoxin A experienced complete disappearance of established tumors. "
08/01/2003 - "Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma."
08/15/1994 - "Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein."
10/01/2003 - "Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy."
08/01/2003 - "NBI-3001 appears to have an acceptable safety and toxicity profile when administered intratumorally in patients with recurrent malignant glioma."
01/01/2003 - "NBI-3001 appears to have an acceptable safety and toxicity profile when administered intratumorally in patients with recurrent malignant glioma."
01/01/2003 - "Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma."
06/01/2000 - "Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma."
|3.||Glioblastoma (Glioblastoma Multiforme)
01/01/1999 - "Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma."
07/01/2005 - "NBI-3001 is a novel immunotoxin of attenuated Pseudomonas exotoxin fused to circularly permutated IL-4, which has shown some antitumor effects in glioblastoma multiforme with intratumoral administration. "
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|1.||Interleukin-4 (Interleukin 4)
|2.||Interleukin-4 Receptors (Interleukin 4 Receptor)